drugset / Trial / NCT04357821
Combinatorial Therapy to Induce an HIV Remission
Phase 1/2
Active not recruiting
11 enrolled
University of California, San Francisco
GeoVax, Inc. · collabIchor Medical Systems Incorporated · collabInternational AIDS Vaccine Initiative · collabMologen AG · collabNational Institute of Allergy and Infectious Diseases (NIAID) · collabRockefeller University · collabamfAR, The Foundation for AIDS Research · collab
NaSingle-groupOpen-labelTreatment
Summary
Combination approaches will almost certainly be required to generate durable control of HIV in the absence of antiretroviral therapy (a "remission"). In this study, 20 individuals will receive a combination regimen administered during ART and then undergo an analytic treatment interruption (ATI).
Timeline
- Start
- 2020-08-01
- Primary completion
- 2026-06
- Completion
- 2026-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 10-1074 | Monoclonal antibody | — | — |
| Subject | MVA/HIV62B | Unknown | — | — |
| Subject | VRC07 | Unknown | — | — |
| Subject | VRC07-523LS | Monoclonal antibody | — | — |
| Subject | lefitolimod | Oligonucleotide (other) | — | — |
| Subject | p24CE | Unknown | — | — |
| Subject | p55gag | Unknown | — | — |
| Background | IL-12 | Protein / enzyme biologic | — | — |